TD Asset Management
IMUX icon

TD Asset Management’s Immunic IMUX Stock Holding History

TD Asset Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,263
Closed -$520K – 1544
2021
Q1 		$520K Buy
3,263
+780
+31% +$132K ﹤0.01% 1389
2020
Q4 		$380K Buy
+2,483
New +$446K ﹤0.01% 1364
2018
Q3 		– Sell
-91
Closed -$249K – 1441
2018
Q2 		$249K Buy
91
+30
+49% +$69.3K ﹤0.01% 1369
2018
Q1 		$165K Buy
+61
New +$140K ﹤0.01% 1324
2015
Q3 		– Sell
-100
Closed -$842K – 1367
2015
Q2 		$842K Buy
100
+58
+138% +$553K ﹤0.01% 998
2015
Q1 		$420K Buy
+42
New +$386K ﹤0.01% 1153

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Asset Management's IMUX Position: Q2 2021 in Review

TD Asset Management sold out of Immunic (IMUX) in Q2 2021, closing a stake of 3,263 shares — an estimated $520K sold.

TD Asset Management first reported a position in IMUX in Q1 2015 and held it in 6 quarters. The position peaked at $842K in Q2 2015. 60 funds tracked by Wall St. Rank hold IMUX as of Q2 2021.

  • TD Asset Management reported no remaining Immunic position as of Q2 2021 after selling out during the quarter.
  • TD Asset Management sold 3,263 Immunic shares in Q2 2021, an estimated $520K.
  • TD Asset Management first reported a position in Immunic in Q1 2015 and held it in 6 quarters.
  • TD Asset Management's Immunic position peaked at $842K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Immunic as of Q2 2021.

Based on TD Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.